Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

Telix is pleased to present a Shareholder Update for the year ended 31 December 2020 and 2020 Annual Report.

In what was an extremely challenging year worldwide, Telix made significant progress with product commercialisation activity, regulatory processes for product approval, and preparing for the Company’s first commercial product launch of the Illuccix® prostate cancer imaging product.

2020 was also a year of strengthening existing and forming new relationships with global academic and commercial partners that will not only help us as we develop new markets and indications for our technology, but also enable us to combine capabilities in ways that have the potential to profoundly impact cancer care.

We wish to thank all our collaborators, shareholders, and our staff as we work towards delivering on our mission, that patients with cancer live longer, better quality lives, and look forward to the continuation of this exciting journey together.

To view the Shareholder Update presentation please click here.

To view the full Annual Report please click here.

To view the Shareholder Update transcript please click here.

The Shareholder Update was recorded and is now available for on-demand public viewing here or listen to the recording below.